531 related articles for article (PubMed ID: 34236381)
21. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy.
Cavanna L; Citterio C; Biasini C; Madaro S; Bacchetta N; Lis A; Cremona G; Muroni M; Bernuzzi P; Lo Cascio G; Schiavo R; Mutti M; Tassi M; Mariano M; Trubini S; Bandieramonte G; Maestri R; Mordenti P; Marazzi E; Vallisa D
Eur J Cancer; 2021 Nov; 157():441-449. PubMed ID: 34601285
[TBL] [Abstract][Full Text] [Related]
22. Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM; Nelli F; Fabbri A; Onorato A; Giannarelli D; Giron Berrios JR; Virtuoso A; Marrucci E; Mazzotta M; Schirripa M; Panichi V; Pessina G; Signorelli C; Chilelli MG; Primi F; Natoni F; Fazio S; Silvestri MA
ESMO Open; 2022 Feb; 7(1):100350. PubMed ID: 34942438
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
24. Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors.
Waldhorn I; Holland R; Goshen-Lago T; Shirman Y; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Peer A; Almog R; Shaked Y; Halberthal M; Ben-Aharon I
Cancer Discov; 2021 Oct; 11(10):2430-2435. PubMed ID: 34475136
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents.
Fenioux C; Teixeira L; Fourati S; Melica G; Lelievre JD; Gallien S; Zalcman G; Pawlotsky JM; Tournigand C
JAMA Oncol; 2022 Apr; 8(4):612-617. PubMed ID: 34994776
[TBL] [Abstract][Full Text] [Related]
26. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.
Amatu A; Pani A; Patelli G; Gagliardi OM; Loparco M; Piscazzi D; Cassingena A; Tosi F; Ghezzi S; Campisi D; Grifantini R; Abrignani S; Siena S; Scaglione F; Sartore-Bianchi A
Eur J Cancer; 2022 Mar; 163():16-25. PubMed ID: 35032813
[TBL] [Abstract][Full Text] [Related]
27. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
[TBL] [Abstract][Full Text] [Related]
28. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
29. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
31. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
J Hematol Oncol; 2021 May; 14(1):81. PubMed ID: 34001183
[TBL] [Abstract][Full Text] [Related]
32. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study.
Shemer A; Pras E; Einan-Lifshitz A; Dubinsky-Pertzov B; Hecht I
JAMA Otolaryngol Head Neck Surg; 2021 Aug; 147(8):739-743. PubMed ID: 34165512
[TBL] [Abstract][Full Text] [Related]
33. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine.
Beharier O; Plitman Mayo R; Raz T; Nahum Sacks K; Schreiber L; Suissa-Cohen Y; Chen R; Gomez-Tolub R; Hadar E; Gabbay-Benziv R; Jaffe Moshkovich Y; Biron-Shental T; Shechter-Maor G; Farladansky-Gershnabel S; Yitzhak Sela H; Benyamini-Raischer H; Sela ND; Goldman-Wohl D; Shulman Z; Many A; Barr H; Yagel S; Neeman M; Kovo M
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34014840
[TBL] [Abstract][Full Text] [Related]
34. Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.
Toepfner N; von Meißner WCG; Strumann C; Drinka D; Stuppe D; Jorczyk M; Moor J; Püschel J; Liss M; von Poblotzki E; Berner R; Moor MB; Chao CM
JAMA Netw Open; 2022 Oct; 5(10):e2237140. PubMed ID: 36255723
[TBL] [Abstract][Full Text] [Related]
35. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel.
Cohen MJ; Oster Y; Moses AE; Spitzer A; Benenson S;
JAMA Netw Open; 2022 Aug; 5(8):e2224657. PubMed ID: 35917125
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Takai R; Nose T; Ohata S; Nagatani Y; Koyama T; Kitao A; Nishimura M; Imamura Y; Kiyota N; Harada K; Tanaka Y; Mori Y; Minami H
J Infect Chemother; 2022 Apr; 28(4):516-520. PubMed ID: 35090826
[TBL] [Abstract][Full Text] [Related]
38. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study.
Yasin AI; Aydin SG; Sümbül B; Koral L; Şimşek M; Geredeli Ç; Öztürk A; Perkin P; Demirtaş D; Erdemoglu E; Hacıbekiroglu İ; Çakır E; Tanrıkulu E; Çoban E; Ozcelik M; Çelik S; Teker F; Aksoy A; Fırat ST; Tekin Ö; Kalkan Z; Türken O; Oven BB; Dane F; Bilici A; Isıkdogan A; Seker M; Türk HM; Gümüş M
Future Oncol; 2022 Mar; 18(10):1235-1244. PubMed ID: 35081732
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]